Recent approvals of Benlysta and Lupkynis highlight a shift towards targeted therapies with improved profiles. Despite challenges like high costs and heterogeneous disease presentation, opportunities ...

United States real-world studies highlight the importance of controlling lupus nephritis to improve patient prognosis.

Greater disease activity and higher proteinuria levels were associated with a greater risk for VTE among patients with LN.

The head of the U.S. Food and Drug Administration’s drug division, Dr. George F. Tidmarsh, resigned on November 2, 2025, one ...

The results of the ALLEGORY trial of Gazyva (obinutuzumab) suggest that the anti-CD20 antibody could have broad utility in ...

Researchers at the University Hospital Bonn (UKB) and the University of Bonn have discovered how a small, naturally occurring ...

Reports suggest that, internally, the Food and Drug Administration is facing a crisis of confidence. Kennedy's reign has been ...

The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented in-person at American Society of Nephrology Kidney Week 2025 November 5–9.

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial ...

An update from Aurinia Pharmaceuticals ( ($AUPH) ) is now available. Aurinia Pharmaceuticals reported significant financial growth for the third ...

Q3 2025 Earnings Call Transcript November 6, 2025 Viatris Inc. beats earnings expectations. Reported EPS is $0.67, ...

Nephrologists must capitalize on new therapeutic agents and opportunities to carry on the momentum of the field, according to ...